지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 193 - 206 (14page)
이용수
초록· 키워드
오류제보하기
Despite several pharmacological options, the clinical outcomes of major depressive disorder (MDD) are often unsatisfactory. Personalized psychiatry attempts to tailor therapeutic interventions according to each patient’s unique profile and characteristics. This approach can be a crucial strategy in improving pharmacological outcomes in MDD and overcoming trial-and-error treatment choices. In this narrative review, we evaluate whether sociodemographic (i.e., gender, age, race/ethnicity, and socioeconomic status) and clinical [i.e., body mass index (BMI), severity of depressive symptoms, and symptom profiles] variables that are easily assessable in clinical practice may help clinicians to optimize the selection of antidepressant treatment for each patient with MDD at the early stages of the disorder. We found that several variables were associated with poorer outcomes for all antidepressants. However, only preliminary associations were found between some clinical variables (i.e., BMI, anhedonia, and MDD with melancholic/atypical features) and possible benefits with some specific antidepressants. Finally, in clinical practice, the assessment of sociodemographic and clinical variables considered in our review can be valuable for early identification of depressed individuals at high risk for poor responses to antidepressants, but there are not enough data on which to ground any reliable selection of specific antidepressant class or compounds. Recent advances in computational resources, such as machine learning techniques, which are able to integrate multiple potential predictors, such as individual/ clinical variables, biomarkers, and genetic factors, may offer future reliable tools to guide personalized antidepressant choice for each patient with MDD.
목차
등록된 정보가 없습니다.
참고문헌 (144)
참고문헌 신청
Murray CJ / 2013 / The state of US health, 1990-2010 : burden of diseases, injuries, and risk factors / JAMA 310:591~608
World Federation for Mental Health / 2012 / Depression: A Global Crisis / World Federation for Mental Health
Greenberg PE / 2015 / The economic burden of adults with major depressive disorder in the United States(2005 and 2010) / J Clin Psychiatry 76:155~162
Kennedy SH / 2016 / Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments / Can J Psychiatry 61:540~560
Fornaro M / 2019 / The FDA “Black Box” warning on antidepressant suicide risk in young adults: more harm than benefits? / Front Psychiatry 10:294
World Federation for Mental Health / 2012 / Depression: A Global Crisis / World Federation for Mental Health
Greenberg PE / 2015 / The economic burden of adults with major depressive disorder in the United States(2005 and 2010) / J Clin Psychiatry 76:155~162
Kennedy SH / 2016 / Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments / Can J Psychiatry 61:540~560
Fornaro M / 2019 / The FDA “Black Box” warning on antidepressant suicide risk in young adults: more harm than benefits? / Front Psychiatry 10:294
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
2018 .01
-
Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response
PSYCHIATRY INVESTIGATION
2016 .01
-
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
PSYCHIATRY INVESTIGATION
2018 .01
-
항우울제 중단 증후군
신경정신의학
2024 .05
-
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
PSYCHIATRY INVESTIGATION
2020 .01
-
Decreased Total Antioxidant Activity in Major Depressive Disorder Patients Non-Responsive to Antidepressant Treatment
PSYCHIATRY INVESTIGATION
2016 .01
-
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
전남의대학술지
2016 .01
-
Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
Clinical Psychopharmacology and Neuroscience
2015 .01
-
우울증과 항우울작용에 관한 p11(S100A10)의 역할
생물정신의학
2016 .01
-
새로운 우울증 치료 약물
생물정신의학
2016 .01
-
주요우울장애의 치료로서 경두개 직류자극술(Transcranial Direct Current Stimulation)의 현재
생물정신의학
2018 .01
-
Gender Differences in Depressive Symptom Profile: Results from Nationwide General Population Surveys in Korea
Journal of Korean Medical Science
2015 .01
-
Multiple Complement Pathway-related Proteins Might Regulate Immunopathogenesis of Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
2023 .05
-
Transcriptional anatomy of the antidepressant actions in the CNS
한국실험동물학회 학술발표대회 논문집
2016 .08
-
Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients
Clinical Psychopharmacology and Neuroscience
2015 .01
-
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
Clinical Psychopharmacology and Neuroscience
2021 .01
-
Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments
Clinical Psychopharmacology and Neuroscience
2021 .11
-
Clinical Significance of the Number of Depressive Symptoms in Major Depressive Disorder: Results from the CRESCEND Study
Journal of Korean Medical Science
2016 .01
-
Diagnostic Issues of Depressive Disorders from Kraepelinian Dualism to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
PSYCHIATRY INVESTIGATION
2019 .01
-
항우울제로 새롭게 등장한 ‘남용 물질’ - 약리학적 기전, 항우울 효과, 오남용 가능성에 대한 고찰
신경정신의학
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0